Nanobiotix (PAR:NANO.PA) received €16 million ($18.5 million) in the first tranche of a previously-announced non-dilutive loan from the European Investment Bank.
The five-year funding deal is designed to support the company’s development of nanoparticle-based cancer therapies.
Get the full story at our sister site, Drug Delivery Business News.
The post Nanobiotix reels in $18.5m tranche from European Investment Bank appeared first on MassDevice.